HRP20240188T1 - Konjugat paklitaksel-hijaluronska kiselina u liječenju nemišićno invazivnog raka mjehura - Google Patents
Konjugat paklitaksel-hijaluronska kiselina u liječenju nemišićno invazivnog raka mjehura Download PDFInfo
- Publication number
- HRP20240188T1 HRP20240188T1 HRP20240188TT HRP20240188T HRP20240188T1 HR P20240188 T1 HRP20240188 T1 HR P20240188T1 HR P20240188T T HRP20240188T T HR P20240188TT HR P20240188 T HRP20240188 T HR P20240188T HR P20240188 T1 HRP20240188 T1 HR P20240188T1
- Authority
- HR
- Croatia
- Prior art keywords
- paclitaxel
- treatment
- prodrug
- bladder cancer
- pharmaceutical composition
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims 10
- 229960003160 hyaluronic acid Drugs 0.000 title claims 10
- 206010005003 Bladder cancer Diseases 0.000 title claims 7
- 210000003205 muscle Anatomy 0.000 title claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 9
- 229960001592 paclitaxel Drugs 0.000 claims 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 238000001212 derivatisation Methods 0.000 claims 4
- 238000011065 in-situ storage Methods 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 3
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 claims 2
- HSUDWURBWSUCOB-NUDIOSPNSA-N 7-(2′,3′′-dihydroxypropyl carbonoxy)paclitaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](OC(=O)OCC(O)CO)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 HSUDWURBWSUCOB-NUDIOSPNSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
| PCT/IB2019/059073 WO2020084525A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
| EP19801630.5A EP3870233B1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240188T1 true HRP20240188T1 (hr) | 2024-05-10 |
Family
ID=65324453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240188TT HRP20240188T1 (hr) | 2018-10-25 | 2019-10-23 | Konjugat paklitaksel-hijaluronska kiselina u liječenju nemišićno invazivnog raka mjehura |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20200397909A1 (enExample) |
| EP (1) | EP3870233B1 (enExample) |
| JP (1) | JP7518815B2 (enExample) |
| KR (1) | KR102913965B1 (enExample) |
| CN (2) | CN119792555A (enExample) |
| CA (1) | CA3112188A1 (enExample) |
| DK (1) | DK3870233T3 (enExample) |
| EA (1) | EA202190614A1 (enExample) |
| ES (1) | ES2971217T3 (enExample) |
| FI (1) | FI3870233T3 (enExample) |
| HR (1) | HRP20240188T1 (enExample) |
| HU (1) | HUE066288T2 (enExample) |
| IT (1) | IT201800009731A1 (enExample) |
| LT (1) | LT3870233T (enExample) |
| MA (1) | MA63879B1 (enExample) |
| PL (1) | PL3870233T3 (enExample) |
| PT (1) | PT3870233T (enExample) |
| RS (1) | RS65193B1 (enExample) |
| SI (1) | SI3870233T1 (enExample) |
| SM (1) | SMT202400021T1 (enExample) |
| WO (1) | WO2020084525A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000007747A1 (it) | 2020-04-10 | 2021-10-10 | Fidia Farm Spa | Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma |
| IT202000008209A1 (it) * | 2020-04-17 | 2021-10-17 | Fidia Farm Spa | Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH666897A5 (fr) | 1983-10-11 | 1988-08-31 | Fidia Spa | Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques. |
| IT1263393B (it) | 1993-07-30 | 1996-08-05 | Fidia Advanced Biopolymers Srl | Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| ITPD20020271A1 (it) | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| US20050080075A1 (en) * | 2003-08-25 | 2005-04-14 | Nichols M. James | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
| ITMI20071267A1 (it) | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| IT1402385B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis |
| IT1402384B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium |
| EP3760707B1 (en) | 2011-11-09 | 2025-11-19 | Fibrobiologics, Inc. | Fibroblasts for use in the treatment of degenerative disc disease |
| IT201600079633A1 (it) | 2016-07-28 | 2018-01-28 | Fidia Farm Spa | Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico |
| CN110859962B (zh) | 2019-11-25 | 2021-01-22 | 山东大学 | 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用 |
-
2018
- 2018-10-25 IT IT102018000009731A patent/IT201800009731A1/it unknown
-
2019
- 2019-10-23 MA MA63879A patent/MA63879B1/fr unknown
- 2019-10-23 LT LTEPPCT/IB2019/059073T patent/LT3870233T/lt unknown
- 2019-10-23 US US16/959,979 patent/US20200397909A1/en not_active Abandoned
- 2019-10-23 SM SM20240021T patent/SMT202400021T1/it unknown
- 2019-10-23 EP EP19801630.5A patent/EP3870233B1/en active Active
- 2019-10-23 KR KR1020217007729A patent/KR102913965B1/ko active Active
- 2019-10-23 PL PL19801630.5T patent/PL3870233T3/pl unknown
- 2019-10-23 HR HRP20240188TT patent/HRP20240188T1/hr unknown
- 2019-10-23 WO PCT/IB2019/059073 patent/WO2020084525A1/en not_active Ceased
- 2019-10-23 DK DK19801630.5T patent/DK3870233T3/da active
- 2019-10-23 CN CN202510138513.7A patent/CN119792555A/zh active Pending
- 2019-10-23 CA CA3112188A patent/CA3112188A1/en active Pending
- 2019-10-23 RS RS20240122A patent/RS65193B1/sr unknown
- 2019-10-23 FI FIEP19801630.5T patent/FI3870233T3/fi active
- 2019-10-23 PT PT198016305T patent/PT3870233T/pt unknown
- 2019-10-23 JP JP2021515655A patent/JP7518815B2/ja active Active
- 2019-10-23 SI SI201831054T patent/SI3870233T1/sl unknown
- 2019-10-23 ES ES19801630T patent/ES2971217T3/es active Active
- 2019-10-23 HU HUE19801630A patent/HUE066288T2/hu unknown
- 2019-10-23 CN CN201980064603.9A patent/CN112805035A/zh active Pending
- 2019-10-23 EA EA202190614A patent/EA202190614A1/ru unknown
-
2021
- 2021-03-17 US US17/204,183 patent/US20210196833A1/en not_active Abandoned
- 2021-05-10 US US17/315,962 patent/US12465649B2/en active Active
-
2023
- 2023-12-14 US US18/539,827 patent/US20240123077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3870233T3 (pl) | 2024-05-06 |
| US20210196833A1 (en) | 2021-07-01 |
| EP3870233B1 (en) | 2023-12-06 |
| KR20210083249A (ko) | 2021-07-06 |
| DK3870233T3 (da) | 2024-02-05 |
| US12465649B2 (en) | 2025-11-11 |
| CA3112188A1 (en) | 2020-04-30 |
| KR102913965B1 (ko) | 2026-01-16 |
| US20210268119A1 (en) | 2021-09-02 |
| CN119792555A (zh) | 2025-04-11 |
| FI3870233T3 (fi) | 2024-02-07 |
| JP2022503771A (ja) | 2022-01-12 |
| EA202190614A1 (ru) | 2021-06-03 |
| HUE066288T2 (hu) | 2024-07-28 |
| RS65193B1 (sr) | 2024-03-29 |
| CN112805035A (zh) | 2021-05-14 |
| ES2971217T3 (es) | 2024-06-04 |
| US20240123077A1 (en) | 2024-04-18 |
| SI3870233T1 (sl) | 2024-03-29 |
| US20200397909A1 (en) | 2020-12-24 |
| MA63879B1 (fr) | 2024-02-29 |
| EP3870233A1 (en) | 2021-09-01 |
| SMT202400021T1 (it) | 2024-03-13 |
| IT201800009731A1 (it) | 2020-04-25 |
| LT3870233T (lt) | 2024-02-26 |
| JP7518815B2 (ja) | 2024-07-18 |
| WO2020084525A1 (en) | 2020-04-30 |
| PT3870233T (pt) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liang et al. | Therapeutic roles of polysaccharides from Dendrobium Officinaleon colitis and its underlying mechanisms | |
| CY1119839T1 (el) | Στερεες μορφες δοσεως μπενταμουστινης | |
| RU2013114411A (ru) | Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер | |
| AR035735A1 (es) | Composicion farmaceutica que se puede administrar por via oral, y el uso de la misma en la fabricacion de un medicamento | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| RU2009133338A (ru) | Композиции, содержащие экстракты cynara scolymus и phaseolus vulgaris, которые полезны для лечения ожирения | |
| CY1111939T1 (el) | Φαρμακευτικο στερεο παρασκευασμα που περιλαμβανει βενζαζεπινες και μεθοδος παρασκευης αυτου | |
| EA201200185A1 (ru) | Фармацевтическая композиция для пероральной доставки дииндолилметана | |
| Haider et al. | Thermogelling platform for baicalin delivery for versatile biomedical applications | |
| MX2022016485A (es) | Derivados de saponina con ventana terapeutica mejorada. | |
| JP2025516384A (ja) | 細胞膜の膜貫通輸送及び流動性を調節する炭素鎖物質、その調製及び使用 | |
| Das et al. | Effect of quercetin on Vibrio cholerae induced nuclear factor-κB activation and interleukin-8 expression in intestinal epithelial cells | |
| Sunder et al. | Antibiotics and nano-antibiotics in treatment of lung infection: In management of COVID-19 | |
| WO2021248254A2 (en) | Pharmacotherapeutic doses of hesperidin or related bioflavonoids to adress infectious and/or inflammatory diseases | |
| FI3870233T3 (fi) | Paklitakseli-Hyaluronihapon konjugaatti käytettäväksi ei-lihasinvasiivisen virtsarakon syövän hoidossa | |
| ES2390226T3 (es) | Tratamiento de enfermedades infecciosas | |
| Willcocks et al. | Revisiting aminocoumarins for the treatment of melioidosis | |
| EA202192291A1 (ru) | Композиция, содержащая стабильную в течение длительного времени живую фекальную микробиоту | |
| JP2022503771A5 (enExample) | ||
| JP2024532611A (ja) | 鼻腔薬物送達用の粘膜接着ポリマー | |
| HRP20171330T1 (hr) | Postupak za proizvodnju i korištenje kopolimera natrijeve karboksimetil celuloze i gosipola | |
| CY1120050T1 (el) | Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων | |
| CN102949387B (zh) | 用于治疗单纯疱疹病毒的组合物和方法 | |
| CN116392478A (zh) | 脱水穿心莲内酯协同增效多黏菌素在制备抗革兰氏阴性菌感染药物中的应用 | |
| CN117337192A (zh) | 用于抑制和治疗病毒感染的组合物和方法 |